Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex

Table 1

Showing patients characteristics and Facial Angiofibroma Severity Index (FASI) score before and after treatment.

Patient number	Age	Sex	Learning disabilities; Present	Pre-erythema; (0/1/2/3)	Pre-size; (1/2/3)	Pre-extension; (2/3)	Pre-FASI	Post-erythema; (0/1/2/3)	Post-size; (1/2/3)	Post-extension; (2/3)	Post-FASI
1	12	♀	Yes	2	3	3	8	0	2	3	5
2	11	♂	No	2	3	3	8	1	2	2	5
3	13	♂	No	2	3	3	8	0	1	3	4
4	14	♀	No	2	3	3	8	1	2	3	6
5	16	♂	No	2	2	3	7	0	1	2	3
6	9	♀	No	2	3	3	8	1	2	3	6
7	17	♀	No	2	3	3	8	1	2	3	6
8	14	♀	Yes	2	2	3	7	1	2	2	5
9	9	♂	Yes	3	3	3	9	2	2	2	6
10	23	♂	No	3	3	3	9	3	3	3	9
11	27	♂	No	3	3	3	9	3	3	3	9
12	24	♀	No	2	3	3	8	1	2	3	6
13	22	♂	Yes	3	3	3	9	2	3	3	8
14	40	♀	Yes	1	3	3	7	0	3	3	6

Erythema. Skin color: 0, light red: 1, red: 2, and dark red/purple: 3. Size. Small (<5 mm): 1, large (>5 mm): 2, and confluent: 3. Extension. <50% cheek area: 2 and >50% cheek area: 3. FASI Score. < or = 5: mild, 6-7: moderate, and = or >8: severe.